Nerve Growth Factors: New Hope For TBI’s, MS, ALS?
Radio Health Journal- December 6, 2020 | Radio Health Journal
Unlike most cells in the human body, the central nervous system cannot repair itself. People who suffer brain or spinal cord injuries, or neurological disorders such as MS and ALS have few alternatives. A neurological researcher describes how he has discovered previously unknown nerve growth factors that could someday allow such injuries and diseases to heal. Dr. Benjamin Segal is quoted.
Breakthrough research shows hope for reversing damage in neurological disease
Multi-Media News Release – October, 26, 2020 | The Ohio State University Wexner Medical Center
Research led by investigators at The Ohio State University Wexner Medical Center provides new hope for recovery from degenerative neurological diseases — such as ALS and multiple sclerosis — as well from as damage caused by traumatic brain and spine injuries and stroke. Dr. Benjamin Segal and Dr. Andrew Sas are quoted.
COVID-19 Hits Black MS Patients Hard
MedPage Today - September 28, 2020 | MedPage Today
COViMS registry gives first look at outcomes among North American patients. Findings were reported at MSVirtual 2020, the joint ACTRIMS-ECTRIMS meeting. Dr. Benjamin Segal is quoted.
Can Tau Predict Early MS Disability?
MedPage Today – September 12, 2020 | MedPage Today
Tau predicted early disability and worse prognosis in multiple sclerosis (MS) patients independently of age, a longitudinal prospective study showed. Findings were reported at MSVirtual 2020, the joint ACTRIMS-ECTRIMS meeting. Dr. Benjamin Segal is quoted.
With Limited Treatment Options, Physicians Often Misclassify SPMS As RRMS
Healio – September 12, 2020 | Healio
Patients with secondary progressive MS on disease-modifying treatments often are clinically misclassified as having relapsing-remitting MS, most likely because they are not reassigned categorically until after conversion has occurred. These findings call into question the use of time to secondary progressive MS (SPMS) conversion as an outcome measure in comparative effectiveness studies that use real-world data, according to the findings presented at MSVirtual2020. Dr. Benjamin Segal provided his perspective.
Greater Ozone Exposure, Genetic Factors Increase Risk For Pediatric MS
Healio – September 12, 2020 | Healio
Ozone levels and DRB1 alleles represent independent factors that correlate with risk for pediatric MS, according to findings presented at MSVirtual2020. Dr. Benjamin Segal shares his perspective.
Multiple Sclerosis Diagnosis: 7 Things to Ask Your Doctor About This Disease
MSN– August 3, 2020| MSN
Scared. Anxious. Numb. Angry. It’s understandable to go through a range of emotions when you receive a multiple sclerosis diagnosis. Even if you have a general idea of what multiple sclerosis is and what it entails, you'll probably have some questions once the initial shock wears off. Dr. Benjamin Segal is quoted
Patient-Related Factors Key To COVID-19 Disease Severity
Medscape – June 1, 2020 | Medscape
Patient-related factors, including age, lymphocytopenia and cytokine levels are associated with COVID-19 disease severity, according to researchers in China. Dr. Benjamin Segal is quoted.
Trials and Tribulations: Neurology Research During COVID-19
Medscape – April 29, 2020 | Medscape
With some pivotal trials on hold, the COVID-19 pandemic is slowing the pace of research in Alzheimer's disease (AD), stroke, and multiple sclerosis (MS). However, researchers remain determined to forge ahead — with many redesigning their studies, at least in part to optimize the safety of their participants and research staff. Dr. Benjamin M. Segal is quoted.
COVID-19 Diary Day 12
WebMD - APRIL 22, 2020 | WebMD
The Challenge of Continuing Clinical Trials, Dr. Benjamin Segal provided his perspective.